Global Osteoarthritis Therapeutics Market Size, Share, Analysis, Industry Report and Forecast 2020-2026
The global osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.2% during the forecast period. Pipeline products are expected to offer an opportunity for the growth of the market. For instance, in April 2019, Pfizer Inc. and Eli Lilly and Co. declared a Phase III study outcomes assessing tanezumab 2.5 mg and 5 mg. This study was intended to compare the 16-week efficacy of tanezumab and long-term joint safety relative to nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with moderate-to-severe osteoarthritis of the knee or hip. 5 mg treatment arm of the tanezumab met two from the three co-primary endpoints related to efficacy, showing a statistically potential improvement in physical function and pain than NSAIDs at the 16-week analysis.
To Request a Sample of our Report on Global Osteoarthritis Therapeutics Market: https://www.omrglobal.com/request-sample/osteoarthritis-therapeutics-market
However, patients who received 2.5 mg tanezumab did not experience a
statistically potential improvement in physical function, pain, or overall
assessment of patients for their osteoarthritis at 16 weeks than NSAIDs. Under
the analysis for safety, there was a potential rate of events regarding joint
safety in the tanezumab arms than NSAIDs at 80 weeks. As a monoclonal antibody,
Tanezumab is part of an investigational drug class of non-opioid chronic pain
medications referred to as nerve growth factor (NGF) inhibitors. These kinds of
pipeline products with increased safety and efficacy are expected to offer an
opportunity for the launch of new therapies in the future, which in turn, will
likely drive the market growth.
Market
Coverage
·
Market
number available for 2019-2026
·
Base
year- 2019
·
Forecast
period- 2020-2026
·
Segment
Covered- By Anatomy and Drug Type
·
Regions
Covered- North America, Europe, Asia-Pacific, and Rest of the World
·
Competitive
Landscape- Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Sanofi S.A.,
and GlaxoSmithKline plc
A
full Report of Global Osteoarthritis Therapeutics Market is Available
at: https://www.omrglobal.com/industry-reports/osteoarthritis-therapeutics-market
Recent
Strategic Initiatives in the Global Osteoarthritis Therapeutics Market
·
In
February 2020, GlaxoSmithKline plc declared the US FDA approval of Voltaren
Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID). It is an arthritis
pain relief available as an OTC product to temporarily provide relief from
arthritis pain in the knee, elbow, hand, ankle, wrist, or foot, in adults (18
years and older). With the approval of the US FDA, Voltaren Arthritis
Pain becomes the first and only prescription-strength, NSAID topical gel for
arthritis pain available OTC in the US. This approval will offer approximately
30 million Americans suffering from osteoarthritis OTC access to the topical
treatment option.
·
In
January 2019, OrthogenRx, Inc. declared the introduction of TriVisc (sodium
hyaluronate) to treat patients with osteoarthritic knee pain who have failed to
get sufficient relief from physical therapy or exercise or simple painkillers.
TriVisc is a highly purified hyaluronic acid (sodium hyaluronate; HA) solution
and supports supplement the viscous properties of the fluid in the knee
joint.
Key questions
addressed by the report
·
What is
the market growth rate?
·
Which
segment/region dominates the market in the base year?
·
Which
segment/region will project the fastest growth in the market?
·
How
COVID-19 impacted the market?
Ć
Recovery
Timeline
Ć
Deviation
from the pre-COVID forecast
Ć
Most
affected region/segment
·
Who is
the leader in the market?
·
How
players are addressing challenges to sustain growth?
·
Where
is the investment opportunity?
Global
Osteoarthritis Therapeutics Market-Segmentation
By Anatomy
·
Knee
·
Ankle
·
Hip
·
Hand
·
Spine
By Drug Type
·
Nonsteroidal
Anti-Inflammatory Drugs (NSAIDs)
·
Viscosupplementation
Agents
·
Corticosteroids
·
Analgesics
Global
Osteoarthritis Therapeutics Market– Segment by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of The World
·
Latin America
·
Middle
East & Africa
Company
Profiles
·
Abbott
Laboratories
·
Anika
Therapeutics, Inc.
·
Assertio
Therapeutics, Inc.
·
Bioventus
LLC
·
Eli
Lilly and Co.
·
Ferring
Pharmaceuticals
·
Fidia
Farmaceutici S.p.A.
·
Flexion
Therapeutics
·
Hanmi
Pharmaceutical Co., Ltd.
·
Horizon
Therapeutics plc
·
Iroko
Pharmaceuticals, Inc.
·
Johnson
& Johnson Service, Inc.
·
Kitov
Pharmaceuticals, Ltd.
·
Laboratorio
Reig Jofre
·
Novartis
International AG
·
OrthogenRx,
Inc
·
Virchow
Biotech, Pvt. Ltd.
Reasons to Buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/osteoarthritis-therapeutics-market
About Orion
Market Research
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports,
consulting and other research-based services.
Media Contact:
Company Name: Orion Market
Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment